Hidradenitis suppurativa is a chronic inflammatory skin condition that presents with painful, deep, and inflamed lesions found in flexural, apocrine gland-bearing sites.
At the 2022 Fall Clinical Dermatology Conference, Joslyn R. Sciacca Kirby, MD, MS, MEd, and Raj Chovatiya, MD, PhD, discussed how there is a large unmet need for hidradenitis suppurativa treatment and what future treatment could look like.
SUNSHINE and SUNRISE trials showed superior efficacy over the placebo.
Study data was presented at EADV 2022 regarding socioeconomic status related to HS.
AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.
Click here to answer this week's poll.
Theodore Rosen, MD, details his top tips for treating hidradenitis suppurativa.
This painful skin disease may lower the odds of live birth and trigger comorbidities.
In this video interview, we sit down with both Jennifer Lin Hsiao, MD, FAAD, and Scott Worswick, MD, FAAD, to talk in detail about their presentation, "Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage."
Almirall announced today that it will work with the University of Michigan to better understand disease drivers in hidradenitis suppurativa.